Key Takeaways MGM reported Q3 EPS of $0.24, missing estimates, while revenues rose 1.6% year over year to $4.25 billion.Strong performance from MGM China and digital operations offset softness in Las Vegas resorts.MGM shares fell 3.8% after hours as EBITDA declined 12% despite record EBITDAR at MGM China.MGM Resorts International (MGM Quick Quote - Free Report ) reported third-quarter 2025 results, with earnings missing the Zacks Consensus Estimate but revenues beating the same by a slight margin. The top ...

For the quarter ended September 2025, NovoCure (NVCR) reported revenue of $167.2 million, up 7.8% over the same period last year. EPS came in at -$0.33, compared to -$0.28 in the year-ago quarter.The reported revenue represents a surprise of +5.76% over the Zacks Consensus Estimate of $158.1 million. With the consensus EPS estimate being -$0.42, the EPS surprise was +21.43%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine ...

公司2025年第三季度财务表现 - 营业收入为51.39亿元，同比增长3.25% [1] - 归属于上市公司股东的净利润为9.79亿元，同比增长38.53% [1] - 归属于上市公司股东的扣除非经常性损益的净利润为8.23亿元，同比增长109.71% [1] - 基本每股收益为0.835元 [1]

LKQ (LKQ) reported $3.5 billion in revenue for the quarter ended September 2025, representing a year-over-year decline of 2.4%. EPS of $0.84 for the same period compares to $0.88 a year ago.The reported revenue represents a surprise of -0.84% over the Zacks Consensus Estimate of $3.53 billion. With the consensus EPS estimate being $0.74, the EPS surprise was +13.51%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their ne ...

整体财务表现 - 2025年第三季度营收为172.8亿美元，同比增长3.7%，超出市场一致预期170.6亿美元，带来1.24%的正向惊喜 [1] - 季度每股收益为2.58美元，远超去年同期的1.57美元，并比市场预期的2.36美元高出9.32% [1] - 过去一个月公司股价回报率为-3.9%，同期标普500指数上涨3.6% [3] 关键产品线销售表现 - 明星肿瘤药Keytruda全球销售额为81.4亿美元，同比增长9.6%，但略低于市场预期的84亿美元 [4] - Keytruda在国际市场销售额为32.6亿美元，同比增长11.4%，低于市场预期的33.3亿美元 [4] - 疫苗产品Gardasil销售额为17.5亿美元，符合市场预期，但同比大幅下降24.2% [4] - 心血管新药Winrevair销售额为3.6亿美元，低于市场预期的4.26亿美元 [4] - 糖尿病药物Janumet在美国市场销售额为7800万美元，同比激增420%，远超市场预期的4282万美元 [4] 各业务板块细分表现 - 动物健康业务销售额为16.2亿美元，同比增长8.6%，高于市场预期的15.6亿美元 [4] - 医院急症护理产品Bridion在美国销售额为3.92亿美元，同比增长15.6%，高于市场预期的3.79亿美元 [4] - 肿瘤联盟产品Lynparza全球销售额为3.79亿美元，同比增长12.5%，高于市场预期的3.44亿美元 [4] - 肿瘤药物Welireg销售额为1.96亿美元，高于市场预期的1.74亿美元 [4] - 抗病毒药物Lagevrio销售额为1.38亿美元，同比下降64%，略低于市场预期的1.44亿美元 [4]

柘中股份10月30日公告，2025年第三季度实现营业收入2.32亿元，同比下降21.33%；归属于上市公司股 东的净利润2.06亿元，同比增长5,282.88%；基本每股收益0.49元。前三季度实现营业收入5.98亿元，同 比下降17.27%；归属于上市公司股东的净利润3.52亿元，同比增长338.55%；基本每股收益0.83元。 ...

翔宇医疗公告，第三季度营收为1.78亿元，同比增长5.46%；净利润为858.69万元，同比下降48.82%。 前三季度营收为5.37亿元，同比增长6.00%；净利润为4398.15万元，同比下降40.09%。 ...

格隆汇10月30日丨清溢光电(688138.SH)公布2025年第三季度报告，营业收入为3.06亿元，同比上升 15.21%；归属于上市公司股东的净利润为5170.70万元，同比上升63.87%；归属于上市公司股东的扣除 非经常性损益的净利润为4737.89万元，同比上升75.29%。 ...

天元股份公告，第三季度营收为2.7亿元，同比增长1.00%；净利润为1819.32万元，同比增长7.32%。前 三季度营收为7.67亿元，同比下降13.35%；净利润为4964.89万元，同比下降1.61%。 ...

达安基因10月30日公告，2025年第三季度实现营业收入1.65亿元，同比下降13.50%；归属于上市公司股 东的净利润4065.64万元，同比增长139.28%；基本每股收益0.03元。前三季度实现营业收入5.04亿元， 同比下降14.81%；归属于上市公司股东的净利润-1.42亿元；基本每股收益-0.1元。 ...